Key facts
- Galux’s last known valuation is $67.8M (Oct 2022).
- It has raised $32.4M; the latest was Later Stage VC ($28.8M) in Feb 2026.
- Notable investors include Korea Development Bank, InterVest, KDB Capital, DAYLI Partners, NH Investment & Securities — 20 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Galux
- ·The full record, as it builds
Funding rounds
No funding rounds for Galux are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Galux
Developer of molecular design technology designed to develop novel drugs against attractive targets. The company's technology leverages the integration of artificial intelligence, physics, and chemistry to design various biomolecules, from small molecules to peptides of several amino acids and larger proteins, helping health professionals treat incurable and rare diseases.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2020
- Employees
- 36
- Website
- galux.co.kr/
- Ownership
- Privately Held (backing)
Galux doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Galux shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Galux in its N-PORT filings yet. We sweep new filings monthly.